Aggregate additional revenue recognition milestone method revenue achieved.

No definition available.

Name:	sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved
Namespace Prefix:	sgmo_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Aggregate additional revenue recognition milestone method revenue eligible to receive.

+ References

No definition available.

+ Details

Name:	sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive
Namespace Prefix:	sgmo_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Aggregate number of gene targets.

+ References

No definition available.

+ Details

Name:	sgmo_AggregateNumberOfGeneTargets
Namespace Prefix:	sgmo_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Collaboration and license agreements number of products approved under agreement.

+ References

No definition available.

+ Details

Name:	sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement
Namespace Prefix:	sgmo_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Initial research term of agreement.

+ References

No definition available.

+ Details

Name:	sgmo_InitialResearchTermOfAgreement
Namespace Prefix:	sgmo_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Milestone payments received.

+ References

No definition available.

+ Details

Name:	sgmo_MilestonePaymentsReceived
Namespace Prefix:	sgmo_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Number of additional gene targets.

+ References

No definition available.

+ Details

Name:	sgmo_NumberOfAdditionalGeneTargets
Namespace Prefix:	sgmo_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of gene targets.

+ References

No definition available.

+ Details

Name:	sgmo_NumberOfGeneTargets
Namespace Prefix:	sgmo_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of initial gene targets.

+ References

No definition available.

+ Details

Name:	sgmo_NumberOfInitialGeneTargets
Namespace Prefix:	sgmo_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of research program.

+ References

No definition available.

+ Details

Name:	sgmo_NumberOfResearchProgram
Namespace Prefix:	sgmo_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.3)
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.10(3))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

+ Details

Name:	us-gaap_DueFromRelatedParties
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(e))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Related Parties
-URI http://asc.fasb.org/extlink&oid=16382449

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07.1(c))
-URI http://asc.fasb.org/extlink&oid=6488393&loc=d3e606610-122999

+ Details

Name:	us-gaap_RevenueFromRelatedParties
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of consideration recognized during the period for the milestone or milestones.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 28
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=68058744&loc=SL6892177-166501

+ Details

Name:	us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.

+ References

+ Details

Name:	us-gaap_RoyaltyRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_CounterpartyNameAxis=sgmo_BiogenIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=sgmo_BetaThalassemiaProjectMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=sgmo_OtherProjectsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=sgmo_ShireAgMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Major Customers, Partnerships and Strategic Alliances - Additional Information (Detail)	1 Months Ended				3 Months Ended		6 Months Ended		12 Months Ended
	Jan. 31, 2016 USD ($)	Jan. 31, 2014 USD ($) Program	Jun. 30, 2012 Targets	Jan. 31, 2012 USD ($) Targets	Jun. 30, 2016 USD ($)	Jun. 30, 2015 USD ($)	Jun. 30, 2016 USD ($) Product Targets	Jun. 30, 2015 USD ($)	Dec. 31, 2014 USD ($)	Sep. 01, 2015 USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Number of research programs \| Program		2
Research and development					$ 19,454,000	$ 15,618,000	$ 34,720,000	$ 30,598,000
Biogen Inc [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenues under agreement		$ 20,000,000
Milestone payments received							$ 0
Number of products approved \| Product							0
Royalty revenues							$ 0
Deferred revenue					7,400,000		7,400,000
Biogen Inc [Member] \| Beta-thalassemia Project [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and development					2,100,000	1,000,000	4,100,000	2,400,000
Biogen Inc [Member] \| Other Projects [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and development					0	1,000,000	100,000	2,100,000
Biogen Inc [Member] \| Maximum [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Potential amount eligible to receive for certain milestones	$ 126,300,000
Potential amount to be funded for achievement of specified commercialized and sales milestones	$ 167,500,000
Shire AG [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenues under agreement				$ 13,000,000
Deferred revenue					4,000,000		4,000,000
Research and development					300,000	$ 4,200,000	$ 700,000	$ 8,700,000
Aggregate number of gene targets \| Targets				7
Number of initial gene targets \| Targets				4
Number of gene targets \| Targets			5
Number of additional gene targets \| Targets			2				1
Recognition of milestone									$ 1,000,000
Amount of obligation related to reimbursement										$ 4,000,000
Revenue recognized related to prior obligations					$ 0		$ 0
Research program to develop laboratory research reagents							6 years